Parkinson Disease Clinical Trial
Official title:
Exercise and Its Cardiovascular Effects in Patients of Parkinson's Disease With Cardiovascular Autonomic Dysfunction
Verified date | March 2024 |
Source | Lawson Health Research Institute |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Abnormalities in the regulation of cardiovascular system due to autonomic nervous system (ANS) dysfunction may lead to a sudden decline in blood pressure (BP) upon standing, sitting or performing activities/exercises in patients with Parkinson's Disease (PD). This sudden decline in BP is known as 'orthostatic hypotension' (OH). OH may cause dizziness and/or black-outs, which may increase the risk of falls. As falls are potentially dangerous and disabling, it is important to prevent their occurrence. Keeping BP within normal range upon change of posture or with activities is therefore of great significance. Pooling of blood in the abdominal blood vessels may be one of the reasons for OH to happen. This research focuses on strengthening the weak abdominal muscles of the participants so that the compressive action of these muscles can help decrease such pooling. Therefore, the researchers hypothesize that strengthening the abdominal muscles shall prove to be helpful in controlling orthostatic hypotension by preventing a sudden decline in blood pressure of the participants upon assumption of upright posture. The secondary hypothesis is that there exists a significant difference in the response of the cardiovascular system to a variety of postures/activities/exercises when patients of PD having cardiovascular autonomic dysfunction are compared with patients of PD with normal ANS function. This study has two parts - stage 1 and stage 2. Only stage 2 is a randomized controlled trial. Stage 1 involves testing the functional integrity of the autonomic nervous system, and observation of the cardiovascular responses of the participants to different postures/activities/exercises and to the use of an abdominal binder (which is a compressive garment worn around the abdomen). Findings of stage 1 shall help the researchers better understand the cardiovascular abnormalities present in such patients at rest and with activity. Stage 2 involves strength training for the abdominal muscles that is to be done by the participant at her/his residence for a period of 3 months followed by a second round of autonomic function testing and observation of the cardiovascular responses to the use of abdominal binder. Findings of stage 2 shall help the researchers determine if strength training of the abdominal muscles can be a useful strategy to counter the cardiovascular abnormalities found in the participants during the testing in stage 1.
Status | Active, not recruiting |
Enrollment | 300 |
Est. completion date | November 28, 2024 |
Est. primary completion date | August 30, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 40 Years to 90 Years |
Eligibility | Inclusion Criteria: - Clinical diagnosis of Parkinson's Disease; - Between stages 2 and 4 of Hoehn and Yahr classification of Parkinson's Disease; - Male or female; and - Age 40-90 years. Exclusion Criteria: - Therapy with anticholinergic, alpha- and beta-adrenergic antagonists or other medication, which could interfere with the regulation of blood pressure and heart rate. These medications are commonly used to treat conditions such as irregular heartbeats, high blood pressure, heart failure, urinary incontinence and other medical conditions (e.g. Alprazolam (Xanax), Amantadine (Symmetrel), Baclofen, Cimetidine, Codeine. Doxazosin, Prazosin, Atenolol (Tenormin), Bisoprolol (Zebeta, also sold as Ziac), Carvedilol (Coreg), Propranolol (Inderal, Inderal LA); - Clinically significant coronary artery disease; - Presence of nerve damage in the peripheral nervous system; - Pregnant or breast feeding females; and - The presence of failure of other organ systems or diseases that can affect autonomic function or the participant's ability to cooperate. These include dementia, specific tumors, heart failure, hypertension, renal or hepatic disease, severe anemia, alcoholism, hypothyroidism, surgical procedures where the nerves of the sympathetic nervous system have been cut, or cerebrovascular disease. |
Country | Name | City | State |
---|---|---|---|
Canada | University Hospital | London | Ontario |
Lead Sponsor | Collaborator |
---|---|
Faizan Ahmed |
Canada,
Diop M, St Lawrence K. Improving the depth sensitivity of time-resolved measurements by extracting the distribution of times-of-flight. Biomed Opt Express. 2013 Mar 1;4(3):447-59. doi: 10.1364/BOE.4.000447. Epub 2013 Feb 15. — View Citation
Dubow JS. Autonomic dysfunction in Parkinson's disease. Dis Mon. 2007 May;53(5):265-74. doi: 10.1016/j.disamonth.2007.02.004. No abstract available. — View Citation
Karvonen J, Vuorimaa T. Heart rate and exercise intensity during sports activities. Practical application. Sports Med. 1988 May;5(5):303-11. doi: 10.2165/00007256-198805050-00002. — View Citation
Pina IL, Balady GJ, Hanson P, Labovitz AJ, Madonna DW, Myers J. Guidelines for clinical exercise testing laboratories. A statement for healthcare professionals from the Committee on Exercise and Cardiac Rehabilitation, American Heart Association. Circulation. 1995 Feb 1;91(3):912-21. doi: 10.1161/01.cir.91.3.912. No abstract available. — View Citation
Ziemssen T, Reichmann H. Cardiovascular autonomic dysfunction in Parkinson's disease. J Neurol Sci. 2010 Feb 15;289(1-2):74-80. doi: 10.1016/j.jns.2009.08.031. Epub 2009 Sep 8. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Blood Pressure | Continuous non-invasive monitoring using a finger cuff. Blood Pressure will be measured in millimetres of Mercury (mmHg). | up to 3 hours for each visit. A total of 2 visits are expected for each participant. | |
Secondary | Heart Rate | Continuous non-invasive monitoring of rate and rhythm of the beating of the heart. It will be measured in beats per minute. | up to 3 hours for each visit. A total of 2 visits are expected for each participant. | |
Secondary | Composite Autonomic Severity Score | This score is the result of the autonomic reflex testing. It combines the sweat volume (in micro-litres), heart rate and blood pressure findings from the autonomic reflex test to provide a discrete numerical value. | Up to one hour for autonomic reflex testing for each visit. A total of 2 visits are expected for each participant. | |
Secondary | Middle Cerebral Artery flow velocity | Continuous monitoring and periodical recording of blood flow velocity in the Middle Cerebral Artery of the brain. It is based on ultrasound technology and is measured on both sides of the head of the participant (left and right sides). The blood flow velocity is expressed in centimetres per second. | Up to three hours for each visit. A total of 2 visits are expected for each participant. | |
Secondary | Changes in the ratio between oxy- and deoxy-hemoglobin | This score is obtained using the Functional Near-Infrared Spectroscopy. This is expressed as a numerical value which has no unit of measurement. | Up to three hours for each visit. A total of 2 visits are expected for each participant. | |
Secondary | The Composite Autonomic Symptom Scale (COMPASS) | The Autonomic Symptom Profile Questionnaire uses the COMPASS scale to generates a score that is obtained using the Autonomic Symptom Profile questionnaire (which is a paper-based self-completed (complete by the patient) questionnaire containing 169 items). The results are expressed in numerical values. The questionnaire evaluates 10 domains related to the functioning of the autonomic nervous system. Higher scores indicate more or worse symptoms. The maximum score for men can be 200 and for women it can be 170, in addition to the 12 questions pertaining to psychosomatic problems where each question carries a maximum score of 10. The autonomic symptom profile questionnaire is used to determine the severity of the symptoms of autonomic nervous system dysfunction. | 20 minutes | |
Secondary | Orthostatic Discriminant and Severity Scores | These scores are obtained using the Orthostatic Discriminant and Severity Scale (ODSS). They are expressed in numerical values. ODSS scale will be used to quantify and discriminate orthostatic symptoms (i.e. symptoms manifested due to low blood pressure upon standing up) from non-orthostatic symptoms (i.e. symptoms which are not caused by low blood pressure upon standing up). ODSS questionnaire is a self-completed instrument and contains 33 questions. There are two types of questions - those that target orthostatic symptoms and others that target non-orthostatic symptoms, thus generating a numerical 'orthostatic score' and a numerical 'non-orthostatic score', respectively. The maximum and minimum orthostatic scores can be 107 and 7, respectively. The maximum and minimum non-orthostatic scores can be 72 and 7, respectively. Higher scores indicate more or worse affected condition of the research participant. | 10 minutes | |
Secondary | Orthostatic Hypotension Questionnaire Score | This score is obtained using the Orthostatic Hypotension Questionnaire. It is expressed in numerical values. The maximum score can be 100 and the minimum score can be zero. This questionnaire is self-completed by the research participant and it is used to determine how low blood pressure symptoms affect the research participants daily life. Higher scores indicate more or worse affected condition of the research participant. | 5 minutes | |
Secondary | Dizziness Handicap Inventory score | This score is obtained using the Dizziness Handicap Inventory. It is expressed in numerical values. The Dizziness Handicap Inventory is a self-completed instrument designed to determine the difficulties the research participant may be facing because of his/her problem of dizziness. It has two parts. The first part has 25 questions divided into 3 domains. The maximum score for part 1 can be 100 and the minimum score can be zero. Part 2 of this instrument has one question with six possible answers. The maximum score for part 2 can 5 and the minimum score can be zero. Higher scores indicate that the research participant is facing greater difficulties in his/her daily life due to the presence of dizziness. | 5 minutes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05415774 -
Combined Deep Brain Stimulation in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04691661 -
Safety, Tolerability, Pharmacokinetics and Efficacy Study of Radotinib in Parkinson's Disease
|
Phase 2 | |
Active, not recruiting |
NCT05754086 -
A Multidimensional Study on Articulation Deficits in Parkinsons Disease
|
||
Completed |
NCT04045925 -
Feasibility Study of the Taïso Practice in Parkinson's Disease
|
N/A | |
Recruiting |
NCT04194762 -
PARK-FIT. Treadmill vs Cycling in Parkinson´s Disease. Definition of the Most Effective Model in Gait Reeducation
|
N/A | |
Completed |
NCT02705755 -
TD-9855 Phase 2 in Neurogenic Orthostatic Hypotension (nOH)
|
Phase 2 | |
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT05830253 -
Free-living Monitoring of Parkinson's Disease Using Smart Objects
|
||
Recruiting |
NCT03272230 -
Assessment of Apathy in a Real-life Situation, With a Video and Sensors-based System
|
N/A | |
Recruiting |
NCT06139965 -
Validity and Reliability of the Turkish Version of the Comprehensive Coordination Scale in Parkinson's Patients
|
||
Completed |
NCT04580849 -
Telerehabilitation Using a Dance Intervention in People With Parkinson's Disease
|
N/A | |
Completed |
NCT03980418 -
Evaluation of a Semiconductor Camera for the DaTSCAN™ Exam
|
N/A | |
Completed |
NCT04477161 -
Effect of Ketone Esters in Parkinson's Disease
|
N/A | |
Completed |
NCT04942392 -
Digital Dance for People With Parkinson's Disease During the COVID-19 Pandemic
|
N/A | |
Terminated |
NCT03446833 -
LFP Beta aDBS Feasibility Study
|
N/A | |
Completed |
NCT03497884 -
Individualized Precise Localization of rTMS on Primary Motor Area
|
N/A | |
Completed |
NCT05538455 -
Investigating ProCare4Life Impact on Quality of Life of Elderly Subjects With Neurodegenerative Diseases
|
N/A | |
Recruiting |
NCT04997642 -
Parkinson's Disease and Movement Disorders Clinical Database
|
||
Completed |
NCT04117737 -
A Pilot Study of Virtual Reality and Antigravity Treadmill for Gait Improvement in Parkinson
|
N/A | |
Recruiting |
NCT03618901 -
Rock Steady Boxing vs. Sensory Attention Focused Exercise
|
N/A |